Kamada Announces First Patient Enrolled into an Investigator-Initiated Clinical Trial of CYTOGAM® to Prevent Cytomegalovirus in Kidney Transplantation false

קמהדע בע"מ	2 380
KAMADA LTD
Corporation no: 511524605	16035

	Israel Securities Authority			Tel Aviv Stock Exchange		C002 ( Public )		Reported via MAGNA:	04/11/2025
	www.isa.gov.il			www.tase.co.il				Reference:	2025-02-083534	Time of broadcast: 11:49 11:49

The corporation scheduled the publication of the report to 04/11/2025 14:00

Immediate Report

Regulation 4 of the Securities Regulations, (Periodic and Immediate Reports of Foreign Corporation) 5761-2000

The corporation is a foreign private issuer as defined by U.S. Securities Laws.

Attached hereto is a report on

Kamada Announces First Patient Enrolled into an Investigator-Initiated Clinical Trial of CYTOGAM® to Prevent Cytomegalovirus in Kidney Transplantation

ea026358701-6k_kamadaEDGAR1_Bannerless_isa.pdf

References of previous documents relating to this matter(the reference does not constitute incorporation by reference):
Stock Exchange/Market: TASE	Date of revision of form structure: 06/08/2024
Address: Holtzman 2 4081 , Rehovot 7670402   ISRAEL , Tel: 08-9406472 , Fax: 08-9406473
E-mail address: Mosheb@kamada.com   Company site: www.kamada.com
Previous names of reporting entity:
Name of the Signatory: מירל אבירן Position of Signatory in the reporting corporation: Name of Employer Company:
Address: ד.נ נגב , בית קמה 8532500 Telephone: 054-5392955 Facsimile: 08-9406473 E-mail: aviranm@kamada.com 2